{"id":819607,"date":"2025-02-27T16:41:33","date_gmt":"2025-02-27T21:41:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-announces-participation-in-march-investor-conferences\/"},"modified":"2025-02-27T16:41:33","modified_gmt":"2025-02-27T21:41:33","slug":"anaptys-announces-participation-in-march-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-announces-participation-in-march-investor-conferences\/","title":{"rendered":"Anaptys Announces Participation in March Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN DIEGO, Feb.  27, 2025  (GLOBE NEWSWIRE) &#8212; AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and\/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences:<\/p>\n<p>\n        <strong>TD Cowen 45<\/strong><br \/>\n        <sup><br \/>\n          <strong>th<\/strong><br \/>\n        <\/sup><br \/>\n        <strong> Annual Healthcare Conference,\u00a0Boston, MA<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>Format \u2013 Fireside chat and one-on-one investor meetings<\/li>\n<li>Date and Time \u2013\u00a0Tuesday, Mar. 4, 2025\u00a0at\u00a01:10pm ET\u00a0\/\u00a010:10am PT<\/li>\n<\/ul>\n<p>\n        <strong>Leerink Partners 2025 Global Healthcare Conference,\u00a0Miami, FL<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>Format \u2013 Fireside chat and one-on-one investor meetings<\/li>\n<li>Date and Time \u2013\u00a0Tuesday, Mar. 11, 2025\u00a0at\u00a010:40am ET\u00a0\/\u00a07:40am PT<\/li>\n<\/ul>\n<p>\n        <strong>Barclays 27<\/strong><br \/>\n        <sup><br \/>\n          <strong>th<\/strong><br \/>\n        <\/sup><br \/>\n        <strong> Annual Global Healthcare Conference,\u00a0Miami, FL<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>Format \u2013 Presentation and one-on-one investor meetings<\/li>\n<li>Date and Time \u2013\u00a0Wednesday, Mar. 12, 2025\u00a0at\u00a08:30am ET\u00a0\/\u00a05:30am PT<\/li>\n<\/ul>\n<p align=\"left\">Live webcasts of the fireside chats and presentation will be available on the investor section of the Anaptys website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qVg0RDZn6bMjMKu-z_wDPb6hsnsKL9Pf15c7nAn-DG2FJ2PDOPvWzoNQ_G1FMDUr7jvUcVuU_XoF3FBp4vHdW96zkTivEDZGQBHZ84PAQFH_73LcfgJ0BXHvW4rMtmrr\" rel=\"nofollow\" target=\"_blank\">http:\/\/ir.anaptysbio.com\/events<\/a>. Replays of the webcasts will be available for at least 30 days following the events.<\/p>\n<p>\n        <strong>About Anaptys<\/strong>\n      <\/p>\n<p>Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead program, rosnilimab, a depleter and agonist targeting PD-1+ T cells, is in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis. Other antibodies in its portfolio include ANB033, a CD122 antagonist, in a Phase 1 trial and ANB101, a BDCA2 modulator, entering a Phase 1 trial. Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (<em>Jemperli<\/em> (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). To learn more, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HYg0ei5ONS9dDvQIi1dO0shmO0z3jmfNdYRPsvlnP9-nzZXOtoVjtxQKrnIgQZUz9oL_QygVJfqIrSOOkEyY8unfPHLPAT0Guc3KZf2dEg4=\" rel=\"nofollow\" target=\"_blank\">www.AnaptysBio.com<\/a>\u00a0or follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=W9v9OGNstxtFddEaGdM4oGKVEYm5Y4MR2pgarIh9tFSBQVNW1J5SHonaMmoFtM2ZQCH3Z4RLxYFpvtocleB94WB6AgzSkRd6bnY5P9TB3kQ=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Nick Montemarano<br \/>Executive Director, Investor Relations<br \/>858.732.0178<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Kq25r2fSVbJI9bv7qka3nhdjXNaYB1vlVlJiXTukVjvTycHNqlLaNJao9aLiKq2KFMDUxt7Ow-sdfrenHVLGTLbp78DmC-6xfyMTLaznAHA=\" rel=\"nofollow\" target=\"_blank\">investors@anaptysbio.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NTQ0MSM2NzgwNzA4IzIwMjAxMjY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MDJiY2YyZjAtZWFlZC00MGI4LWJiZTktNTRmYzFmODkxNTI5LTEwMzE2OTg=\/tiny\/AnaptysBio-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) &#8212; AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and\/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences: TD Cowen 45 th Annual Healthcare Conference,\u00a0Boston, MA Format \u2013 Fireside chat and one-on-one investor meetings Date and Time \u2013\u00a0Tuesday, Mar. 4, 2025\u00a0at\u00a01:10pm ET\u00a0\/\u00a010:10am PT Leerink Partners 2025 Global Healthcare Conference,\u00a0Miami, FL Format \u2013 Fireside chat and one-on-one investor meetings Date and Time \u2013\u00a0Tuesday, Mar. 11, 2025\u00a0at\u00a010:40am ET\u00a0\/\u00a07:40am PT Barclays 27 th Annual Global Healthcare Conference,\u00a0Miami, FL Format \u2013 Presentation and one-on-one investor meetings Date and Time \u2013\u00a0Wednesday, Mar. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-announces-participation-in-march-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Anaptys Announces Participation in March Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-819607","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Anaptys Announces Participation in March Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-announces-participation-in-march-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anaptys Announces Participation in March Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) &#8212; AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and\/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences: TD Cowen 45 th Annual Healthcare Conference,\u00a0Boston, MA Format \u2013 Fireside chat and one-on-one investor meetings Date and Time \u2013\u00a0Tuesday, Mar. 4, 2025\u00a0at\u00a01:10pm ET\u00a0\/\u00a010:10am PT Leerink Partners 2025 Global Healthcare Conference,\u00a0Miami, FL Format \u2013 Fireside chat and one-on-one investor meetings Date and Time \u2013\u00a0Tuesday, Mar. 11, 2025\u00a0at\u00a010:40am ET\u00a0\/\u00a07:40am PT Barclays 27 th Annual Global Healthcare Conference,\u00a0Miami, FL Format \u2013 Presentation and one-on-one investor meetings Date and Time \u2013\u00a0Wednesday, Mar. &hellip; Continue reading &quot;Anaptys Announces Participation in March Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-announces-participation-in-march-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-27T21:41:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NTQ0MSM2NzgwNzA4IzIwMjAxMjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptys-announces-participation-in-march-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptys-announces-participation-in-march-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Anaptys Announces Participation in March Investor Conferences\",\"datePublished\":\"2025-02-27T21:41:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptys-announces-participation-in-march-investor-conferences\\\/\"},\"wordCount\":295,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptys-announces-participation-in-march-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4NTQ0MSM2NzgwNzA4IzIwMjAxMjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptys-announces-participation-in-march-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptys-announces-participation-in-march-investor-conferences\\\/\",\"name\":\"Anaptys Announces Participation in March Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptys-announces-participation-in-march-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptys-announces-participation-in-march-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4NTQ0MSM2NzgwNzA4IzIwMjAxMjY=\",\"datePublished\":\"2025-02-27T21:41:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptys-announces-participation-in-march-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptys-announces-participation-in-march-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptys-announces-participation-in-march-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4NTQ0MSM2NzgwNzA4IzIwMjAxMjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4NTQ0MSM2NzgwNzA4IzIwMjAxMjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptys-announces-participation-in-march-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anaptys Announces Participation in March Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anaptys Announces Participation in March Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-announces-participation-in-march-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Anaptys Announces Participation in March Investor Conferences - Market Newsdesk","og_description":"SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) &#8212; AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and\/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences: TD Cowen 45 th Annual Healthcare Conference,\u00a0Boston, MA Format \u2013 Fireside chat and one-on-one investor meetings Date and Time \u2013\u00a0Tuesday, Mar. 4, 2025\u00a0at\u00a01:10pm ET\u00a0\/\u00a010:10am PT Leerink Partners 2025 Global Healthcare Conference,\u00a0Miami, FL Format \u2013 Fireside chat and one-on-one investor meetings Date and Time \u2013\u00a0Tuesday, Mar. 11, 2025\u00a0at\u00a010:40am ET\u00a0\/\u00a07:40am PT Barclays 27 th Annual Global Healthcare Conference,\u00a0Miami, FL Format \u2013 Presentation and one-on-one investor meetings Date and Time \u2013\u00a0Wednesday, Mar. &hellip; Continue reading \"Anaptys Announces Participation in March Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-announces-participation-in-march-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-27T21:41:33+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NTQ0MSM2NzgwNzA4IzIwMjAxMjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-announces-participation-in-march-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-announces-participation-in-march-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Anaptys Announces Participation in March Investor Conferences","datePublished":"2025-02-27T21:41:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-announces-participation-in-march-investor-conferences\/"},"wordCount":295,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-announces-participation-in-march-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NTQ0MSM2NzgwNzA4IzIwMjAxMjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-announces-participation-in-march-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-announces-participation-in-march-investor-conferences\/","name":"Anaptys Announces Participation in March Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-announces-participation-in-march-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-announces-participation-in-march-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NTQ0MSM2NzgwNzA4IzIwMjAxMjY=","datePublished":"2025-02-27T21:41:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-announces-participation-in-march-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-announces-participation-in-march-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-announces-participation-in-march-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NTQ0MSM2NzgwNzA4IzIwMjAxMjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NTQ0MSM2NzgwNzA4IzIwMjAxMjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-announces-participation-in-march-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Anaptys Announces Participation in March Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/819607","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=819607"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/819607\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=819607"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=819607"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=819607"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}